Literature DB >> 11418643

An immunodominant MHC class II-restricted tumor antigen is conformation dependent and binds to the endoplasmic reticulum chaperone, calreticulin.

D Golgher1, F Korangy, B Gao, K Gorski, E Jaffee, M Edidin, D M Pardoll, T Elliott.   

Abstract

There is accumulating evidence that CD4(+) T cell responses are important in antitumor immunity. Accordingly, we generated CD4(+) T cells against the murine CT26 colon cancer. Three of three independent CT26-specific CD4(+) hybridomas were found to recognize the high m.w. precursor of the env gene product gp90. The CD4(+) response was completely tumor specific in that the same glycoprotein expressed by other tumors was not recognized by the CT26-specific hybridomas. The recognition of gp90 by the hybridomas was strictly dependent on the conformation of gp90. Different procedures that disrupted the conformation of the glycoprotein, such as disulfide bond reduction and thermal denaturation, completely abrogated recognition of gp90 by all three hybridomas. In CT26 cells, but not in other tumor cells tested, a large proportion of gp90 was retained in the endoplasmic reticulum, mostly bound to the endoplasmic reticulum chaperone, calreticulin. Although calreticulin was not essential for the stimulation of the gp90-specific hybridomas, most of the antigenic form of gp90 was bound to it. The antigenicity of gp90 correlated well with calreticulin binding, reflecting the fact that specificity of binding of calreticulin to its substrate required posttranslational modifications that were also necessary for the generation of this tumor-specific CD4(+) epitope.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11418643     DOI: 10.4049/jimmunol.167.1.147

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Processing of tumor antigen differentially impacts the development of helper and effector CD4+ T-cell responses.

Authors:  Dannie Bernard; Michael S Ventresca; Laura A Marshall; Carole Evelegh; Yonghong Wan; Jonathan L Bramson
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

2.  Tumour secreted grp170 chaperones full-length protein substrates and induces an adaptive anti-tumour immune response in vivo.

Authors:  Hilal Arnouk; Evan R Zynda; Xiang-Yang Wang; Bonnie L Hylander; Masoud H Manjili; Elizabeth A Repasky; John R Subjeck; A Latif Kazim
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

3.  Immunization against endogenous retroviral tumor-associated antigens.

Authors:  M H Kershaw; C Hsu; W Mondesire; L L Parker; G Wang; W W Overwijk; R Lapointe; J C Yang; R F Wang; N P Restifo; P Hwu
Journal:  Cancer Res       Date:  2001-11-01       Impact factor: 12.701

4.  Age-dependent tolerance to an endogenous tumor-associated antigen.

Authors:  Jennifer A McWilliams; Richard T Sullivan; Kimberly R Jordan; Rachel H McMahan; Charles B Kemmler; Marcia McDuffie; Jill E Slansky
Journal:  Vaccine       Date:  2008-02-20       Impact factor: 3.641

5.  Folding of an MHC class II-restricted tumor antigen controls its antigenicity via MHC-guided processing.

Authors:  Yusuke Mimura; Yuka Mimura-Kimura; Katie Doores; Denise Golgher; Benjamin G Davis; Raymond A Dwek; Pauline M Rudd; Tim Elliott
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-26       Impact factor: 11.205

Review 6.  The intrinsic immunogenic properties of cancer cell lines, immunogenic cell death, and how these influence host antitumor immune responses.

Authors:  Tania Løve Aaes; Peter Vandenabeele
Journal:  Cell Death Differ       Date:  2020-11-19       Impact factor: 15.828

7.  Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers.

Authors:  Rod Balhorn; Monique Cosman Balhorn
Journal:  Oncotarget       Date:  2020-09-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.